<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04797260</url>
  </required_header>
  <id_info>
    <org_study_id>L20.067</org_study_id>
    <nct_id>NCT04797260</nct_id>
  </id_info>
  <brief_title>Phase I/II Clinical Trial Stem Cell Gene Therapy in RAG1-Deficient SCID</brief_title>
  <acronym>RAG1-SCID</acronym>
  <official_title>Phase I/II Clinical Trial of Autologous Hematopoietic Stem Cell Gene Therapy in RAG1-Deficient Severe Combined Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Leiden University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, non-randomized, open-label, two-centre phase I/II intervention&#xD;
      study designed to treat children up to 24 months of age with RAG1-deficient SCID with an&#xD;
      indication for allogeneic hematopoietic stem cell transplantation but lacking an HLA-matched&#xD;
      donor. The study involves infusion of autologous CD34+ cells transduced with the&#xD;
      pCCL.MND.coRAG1.wpre lentiviral vector (hereafter called RAG1 LV CD34+ cells) in five&#xD;
      patients with RAG1-deficient SCID.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe combined immunodeficiency (SCID) is a genetically heterogeneous life-threatening&#xD;
      disease characterized by severely impaired T cell development with or without impaired&#xD;
      natural killer (NK) and B cell development or function depending on the genetic defect.&#xD;
      Mutations in recombination activating genes 1 and 2 (RAG1 and RAG2) represent about 20% of&#xD;
      all types of SCID. SCID is a paediatric emergency since it leads to severe and recurrent&#xD;
      infections often in combination with protracted diarrhoea and failure to thrive. When left&#xD;
      untreated, it is usually fatal within the first year of life. Currently, the only curative&#xD;
      treatment option for RAG-deficient SCID is allogeneic hematopoietic stem cell transplantation&#xD;
      (HSCT). Despite improvements in HSCT in recent years, this treatment is associated with&#xD;
      serious potential complications like graft-versus-host disease which results in an&#xD;
      unfavourable outcome, particularly in patients who lack a human leukocyte antigen&#xD;
      (HLA)-matched donor. In recent years, gene therapy based on transplantation of autologous&#xD;
      gene-corrected hematopoietic stem cells (HSC) has evolved as an effective and safe&#xD;
      therapeutic option for X-linked and ADA-deficient forms of SCID. We have recently&#xD;
      demonstrated that gene therapy using lentiviral (LV) self-inactivating (SIN) vectors&#xD;
      expressing codon-optimized human RAG1 in a mouse model for RAG1-deficient SCID effectively&#xD;
      restores T and B cell development and function. In this phase I/II explorative intervention&#xD;
      study feasibility, safety and efficacy of gene therapy using gene-corrected autologous&#xD;
      CD34+-selected mobilized peripheral blood or bone marrow cells will be investigated in&#xD;
      patients with RAG1-deficient SCID with an indication for allogeneic HSCT but lacking an human&#xD;
      leukocyte antigen (HLA)-matched donor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>CD34+ HSC from patient will be obtained by leukapheresis or from bone marrow. After purification, CD34+ cells will be transduced with the SIN-LV-RAG1 vector. Transduced cells will be cryopreserved. Upon confirmation of successful transduction and meeting the release criteria as RAG1 LV CD34+ cells, patient conditioning will be allowed to start. After patient conditioning, cryopreserved RAG1 LV CD34+ cells will be thawed and administered to the patient. In case of failure of hematopoietic reconstitution after infusion of the RAG1 LV CD34+ cells the autologous backup graft will be infused to rescue the patient from aplasia. In addition, a conventional allogeneic HSCT procedure will be scheduled. Patients included in this study will be monitored on protocol during the first two years after infusion of the RAG1 LV CD34+ cells as per study protocol. Follow up as part of the routine clinical care for post-transplant patients will be annual after this, for at least 15 years after infusion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of successful generation of RAG1 LV CD34+ cells</measure>
    <time_frame>2 years</time_frame>
    <description>IMP (RAG1 LV CD34+ cells) that meets the release criteria as defined in the IMPD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of RAG1 lentiviral gene therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival and event-free survival (EFS) after infusion of the IMP with events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>T cell reconstitution</measure>
    <time_frame>1 year</time_frame>
    <description>CD3 T cells &gt; 300/μL and CD4 &gt; 200/μL at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thymic function</measure>
    <time_frame>1 year</time_frame>
    <description>presence of naïve CD4 T cells at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T and B cell receptor repertoire</measure>
    <time_frame>1 year</time_frame>
    <description>Molecular T and B cell receptor repertoire at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin dependence</measure>
    <time_frame>2 years</time_frame>
    <description>Immunoglobulin supplementation dependence at 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of gene marking</measure>
    <time_frame>1 year</time_frame>
    <description>Gene marking in myeloid and lymphoid lineages in blood at six months and one year and in bone marrow at one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Infections</measure>
    <time_frame>2 years</time_frame>
    <description>Frequency of serious/invasive infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure to thrive</measure>
    <time_frame>2 years</time_frame>
    <description>Recovery from failure to thrive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Quality of life at 2 years (assessed using PedsQL by proxy).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Severe Combined Immunodeficiency Due to RAG1 Deficiency</condition>
  <arm_group>
    <arm_group_label>Gene therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm, 5 patients will be included for gene therarpy</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Gene therapy</intervention_name>
    <description>Patients will be infused with autologous CD34+ cells transduced with the pCCL.MND.coRAG1.wpre lentiviral vector (RAG1 LV CD34+ cells).</description>
    <arm_group_label>Gene therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. RAG1-deficient SCID as confirmed by genetic analysis&#xD;
&#xD;
          2. Peripheral blood T cells &lt; 300/μL and/or naïve T cells &lt; 1/μL&#xD;
&#xD;
          3. Age &lt; 2 years&#xD;
&#xD;
          4. Age at least 8 weeks by the time of busulfan and fludarabine administration&#xD;
&#xD;
          5. Lack of an available HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR,&#xD;
             DQ) allele-matched (un)related donor)&#xD;
&#xD;
          6. Signed informed consent (parental or guardian)&#xD;
&#xD;
          7. Able to return to the study centre for follow-up (per protocol) during the 2-year&#xD;
             study and the 15-year long-term off study review&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Availability of an HLA-matched donor (HLA-identical sibling or 10/10 (A, B, C, DR, DQ)&#xD;
             allele-matched (un)related donor)&#xD;
&#xD;
          2. RAG1 deficiency with peripheral blood T cells &gt; 300/μL and/or naïve T cells &gt; 1/μL&#xD;
&#xD;
          3. Omenn syndrome&#xD;
&#xD;
          4. Previous allogeneic HSCT&#xD;
&#xD;
          5. Significant organ dysfunction/co-morbidity (including but not limited to the ones&#xD;
             listed below):&#xD;
&#xD;
               1. Mechanical ventilation&#xD;
&#xD;
               2. Shortening fraction on echocardiogram &lt;25%&#xD;
&#xD;
               3. Renal failure defined as dialysis dependence&#xD;
&#xD;
               4. Uncontrolled seizure disorder&#xD;
&#xD;
          6. any other medical condition which, in the opinion of the treating physician, would&#xD;
             interfere with the good conduction of the clinical trial (e.g. contraindications for&#xD;
             stem cell harvest or administration of conditioning medication)&#xD;
&#xD;
          7. Human immunodeficiency virus (HIV) infection or Human T-cell Leukemia Virus (HTLV)&#xD;
             infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Weeks</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arjan C Lankester, Prof.dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Leiden University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arjan C Lankester, Prof. Dr.</last_name>
    <phone>0031715264871</phone>
    <email>A.Lankester@lumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Estefania Laney, MSc.</last_name>
    <phone>0031715296242</phone>
    <email>e.laney@lumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300RC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arjan Lankester, prof dr</last_name>
      <phone>0031715264131</phone>
      <email>a.lankester@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Estefania Laney, MSc</last_name>
      <phone>0031715262806</phone>
      <email>e.laney@lumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Garcia-Perez L, van Eggermond M, van Roon L, Vloemans SA, Cordes M, Schambach A, Rothe M, Berghuis D, Lagresle-Peyrou C, Cavazzana M, Zhang F, Thrasher AJ, Salvatori D, Meij P, Villa A, Van Dongen JJM, Zwaginga JJ, van der Burg M, Gaspar HB, Lankester A, Staal FJT, Pike-Overzet K. Successful Preclinical Development of Gene Therapy for Recombinase-Activating Gene-1-Deficient SCID. Mol Ther Methods Clin Dev. 2020 Mar 31;17:666-682. doi: 10.1016/j.omtm.2020.03.016. eCollection 2020 Jun 12.</citation>
    <PMID>32322605</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Leiden University Medical Center</investigator_affiliation>
    <investigator_full_name>alankester</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>SCID</keyword>
  <keyword>RAG1</keyword>
  <keyword>Gene Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

